SuperworthHealth Catalyst HCAT
- Market cap
- $127.2M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 0.4×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $292.2M
- −8% on a year ago
- Net margin
- −90.6%
- Free cash flow yield
- 21.2%
Health Catalyst trades at 0.4× sales. Its trailing earnings are negative, so it has no PE. Revenue was $292.2M over the last twelve months, down 8% on a year earlier with a −91% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $73.8M+8% | $75.1M+9% | $74.7M+1% | $75.9M+4% | $76.4M+4% | $79.6M+6% | $79.4M+6% | $80.7M+6% | $76.3M+0% | $74.7M−6% | $70.8M−11% | $70.5M−13% | |
| Cost of revenue | $41.8M+15% | $44.6M+17% | $38.5M+1% | $40.1M+2% | $42.3M+1% | $44.9M+1% | $43.2M+12% | $42.5M+6% | $38.5M−9% | $35.3M−21% | $35.3M−18% | $35.6M−16% |
| Gross profit | $32M−0% | $30.5M−2% | $36.2M+2% | $35.8M+6% | $34M+6% | $34.7M+14% | $36.2M+0% | $38.2M+7% | $37.8M+11% | $39.4M+14% | $35.5M−2% | $34.9M−9% |
| R&D | $17.7M−15% | $20.3M+3% | $14.9M−13% | $13.9M−21% | $14.2M−20% | $15M−26% | $15.2M+2% | $12.4M−11% | $12.3M−14% | $9.9M−34% | $9.8M−36% | $11M−11% |
| SG&A | $28.7M−36% | $32.7M−11% | $33.6M−21% | $27.1M−32% | $23.6M−18% | $26.9M−18% | $28.9M−14% | $21.5M−21% | $30.4M+29% | $21.2M−21% | $24.5M−15% | $22.3M+4% |
| −$24.6M−46% | −$32.8M−11% | −$22.8M−35% | −$15.8M−54% | −$13.7M−44% | −$17.5M−47% | −$20.2M−12% | −$37.1M+135% | −$17.5M+28% | −$86.1M+392% | −$106.5M+428% | −$36.5M−2% | |
| Pre-tax income | −$22M−52% | −$30.2M−16% | −$20.5M−38% | −$13.4M−59% | −$15.2M−31% | −$20M−34% | −$23.5M+15% | −$40.9M+204% | −$22.2M+46% | −$90.6M+352% | −$110.6M+370% | −$40.2M−2% |
| $59K−62% | $143K+142% | $113K+64% | $70K−18% | −$475K | $625K+337% | $215K+90% | $81K+16% | $41K | $379K−39% | $414K+93% | $315K+289% | |
| Net income | −$22M−52% | −$30.3M−15% | −$20.6M−38% | −$13.5M−59% | −$14.7M−33% | −$20.7M−32% | −$23.7M+15% | −$41M+203% | −$22.2M+51% | −$91M+340% | −$111M+368% | −$40.5M−1% |
| −$0.39−54% | −$0.53−20% | −$0.35−42% | −$0.23−60% | −$0.24−39% | −$0.33−38% | −$0.35+0% | −$0.59+157% | −$0.32+33% | −$1.28+288% | −$1.53+337% | −$0.55−7% | |
| 56.7M+4% | 57.5M+7% | 58.6M+6% | 59.3M+6% | 60.4M+7% | 62.4M+9% | 68.6M+17% | 69.6M+17% | 70.4M+16% | 71M+14% | 72.6M+6% | 74M+6% |
Revenue: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.
Cost of revenue: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.
Gross profit: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them. 32 periods, Q2 FY18 to Q2 FY26: not printed by the filing, worked out from its own lines.
R&D: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.
SG&A: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.
Operating income: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.
Income tax: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.
Net income: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.
EPS, diluted: 10 periods, Q1 FY18 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY18: share-days: the 6-month average less the second quarter's. 8 periods, Q4 FY18 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Software - Application nearest Health Catalyst's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| HCATHealth Catalyst | $127.2M | n/m | n/a | 0.4× | −8% | −90.6% | |
| TRAKReposiTrak | $133.2M | 18.8× | 44.6× | 5.7× | +3% | 32.5% | |
| ALISCalisa Acquisition | $75.5M | 64.0× | 72.9× | n/m | n/m | n/m | |
| EGHT8X8 | $307.6M | 53.3× | 57.5× | 0.4× | +4% | 0.6% | |
| TZOOTravelzoo | $51.7M | 169× | 20.1× | 0.6× | +5% | 0.5% | |
| ZIPZiprecruiter | $382.4M | 13.3× | 30.9× | 0.8× | +0% | 6.2% | |
| OOMAOoma | $545.7M | 52.0× | 124× | 1.8× | +17% | 3.6% | |
| CARSCars.com | $585.6M | 19.2× | 27.3× | 0.8× | +1% | 4.7% | |
| IBEXIBEX | $627.1M | 15.1× | 11.5× | 1.0× | +15% | 7.2% | |
| NRDSNerdwallet | $698.7M | 12.3× | 15.9× | 0.8× | +12% | 7.6% | |
| MNTNMNTN | $724.1M | 12.9× | 15.1× | 2.3× | +21% | 18.0% | |
| Peer median | $464M | 19.0× | 29.1× | 0.8× | +5% | 6.2% |
More on Health Catalyst
Each number over time
- PE ratio
- Price to sales ratio
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
Its groups
About
- Industry
- Software - Application
- Sector
- Technology
Valuation data, not investment advice. Prices as of .